ライフサイエンスコーパス: multivessel disease

1 ne vessel (13 with single-vessel and 17 with multivessel disease).

2 is now commonly used to treat patients with multivessel disease.

3 in insulin-requiring diabetic patients with multivessel disease.

4 n of left ventricular function and extent of multivessel disease.

5 the other diseased vessels in patients with multivessel disease.

6 patterns for patients with single-vessel and multivessel disease.

7 is of > or = 50% and 114 patients (55%) with multivessel disease.

8 nd moderately sensitive (68%, 77 of 114) for multivessel disease.

9 outcome than was angiographically determined multivessel disease.

10 perfusion capacity in eligible patients with multivessel disease.

11 h single-vessel disease, and 22 (25.3%) with multivessel disease.

12 morbidities, including cardiogenic shock and multivessel disease.

13 rm safety of FFR-guided PCI in patients with multivessel disease.

14 onary intervention (PCI) among patients with multivessel disease.

15 segment-elevation myocardial infarction have multivessel disease.

16 e analysis was restricted to only those with multivessel disease.

17 was cost-effective as compared with PTCA for multivessel disease.

18 onary atherosclerosis and more than half had multivessel disease.

19 DASE was greater specificity, especially for multivessel disease.

20 coronary artery bypass surgery, and 65% had multivessel disease.

21 n data has shown to improve the detection of multivessel disease.

22 ts, aged patients had a higher prevalence of multivessel disease (16.5% vs. 9.6%, p = 0.001), unstabl

23 d no significant change in the prevalence of multivessel disease (24 percent in 1980-1981 and 23 perc

24 25.5 vs. 40.1%, p = 0.047), anterior MI, and multivessel disease (34.8 vs. 77.8%, p < 0.001) and a sh

25 ction <14 days = 7; elevated creatinine = 4; multivessel disease = 4; and age >65 years = 3.

26 rfusion defects were similarly sensitive for multivessel disease (72%, 42/58 vs. 66%, 38/53, respecti

27 g 16,089 patients with diabetes mellitus and multivessel disease, 8096 patients with similar propensi

28 Multivessel disease (87% versus 74%, P = .01) was more f

29 84%, 51/61 vs. 74%, 45/61, respectively) and multivessel disease (91%, 53/58 vs. 86%, 50/58, respecti

30 luding older age, extreme body mass indexes, multivessel disease, a lower ejection fraction, unstable

31 l, we randomly assigned 706 patients who had multivessel disease, acute myocardial infarction, and ca

32 coronary artery disease in both single- and multivessel disease and detects more subendocardial isch

33 The accuracy was high in single-vessel and multivessel disease and independent of CAD location.

34 Bypass surgery for patients with multivessel disease and ISR provided the best outcomes.

35 heart failure class III or higher, thrombus, multivessel disease and older age.

36 e the elevated risk of CABG in patients with multivessel disease and planned IR remains to be determi

37 Patients with multivessel disease and severe left ventricular systolic

38 Among patients with multivessel disease and severe left ventricular systolic

39 percutaneous coronary intervention (PCI) for multivessel disease and severe left ventricular systolic

40 particularly in patients with more extensive multivessel disease and the greatest degree of left vent

41 eous coronary interventions in patients with multivessel disease and the recent introduction of drug-

42 occurred within the context of a decline in multivessel disease and thus likely reflect the natural

43 ity (p = 0.036) were higher in patients with multivessel disease and were similar for both treatment

44 lder, women, hypertensive and diabetic, with multivessel disease and with reduced left ventricular fu

45 (131 had single-vessel disease [SVD]; 30 had multivessel disease), and 310 (60.1%) had >/=50% stenosi

46 oronary artery disease, P = 0.81 for that of multivessel disease, and P = 0.57 for the mean degree of

47 , previous angioplasty or bypass surgery and multivessel disease, and we sequentially compared Braunw

48 yocardial infarction, cardiogenic shock, and multivessel disease, and were associated with higher mor

49 rity of patients with cardiogenic shock have multivessel disease, and whether PCI should be performed

50 der the curve, 0.88 versus 0.73; P<0.001) or multivessel disease (area under the curve, 0.98 versus 0

51 y significant coronary artery disease and of multivessel disease, assessed the mean degree of stenosi

52 rdiac-related health status in patients with multivessel disease at 6- and 12-month follow-up.

53 t of 2013) of those patients identified with multivessel disease at NCDR sites had had 0- or 1-vessel

54 PCI are performed in older patients to treat multivessel disease, but their comparative effectiveness

55 ascularisation of patients with diabetes and multivessel disease by CABG decreases long-term mortalit

56 For patients with multivessel disease, CABG continues to be associated wit

57 For patients with multivessel disease, CABG provided a survival advantage

58 In subgroup analysis of multivessel disease, CABG provided significant survival

59 ment-elevation acute coronary syndromes with multivessel disease, choice of revascularization modalit

60 isk of adverse events, a higher incidence of multivessel disease, complex lesions, and visible thromb

61 Among patients with multivessel disease, contemporary PCI resulted in safer

62 In patients with diabetes mellitus and multivessel disease, coronary artery bypass graft surger

63 ICERs, including patients with >1 prior MI, multivessel disease, diabetes, renal dysfunction (all wi

64 detect residual infarct artery stenosis and multivessel disease during the first week after acute my

65 In patients with diabetes mellitus and multivessel disease, EES was associated with lower upfro

66 ith Diabetes mellitus: Optimal management of Multivessel disease [FREEDOM]; NCT00086450).

67 arction, inoperable or high surgical risk or multivessel disease had significantly higher 5-year card

68 G for ISR, mainly because of the presence of multivessel disease, had significantly better outcomes t

69 clinical trial evaluated STEMI patients with multivessel disease having PPCI within 12 h of symptom o

70 Multivessel disease identified through DSE was more pred

71 who underwent angiography (p < 0.001), with multivessel disease in 63% versus 13% (p < 0.001).

72 In patients presenting for P-PCI with multivessel disease, index admission complete revascular

73 In patients with multivessel disease, index segment revascularization was

74 vascularization of symptomatic patients with multivessel disease involving the LAD is warranted.

75 -segment-elevation myocardial infarction and multivessel disease is uncertain.

76 neous coronary intervention in patients with multivessel disease is unclear in that there is little i

77 te and high-risk acute coronary syndrome and multivessel disease managed with percutaneous coronary i

78 rvention (PCI) in patients with diabetes and multivessel disease, managed with or without insulin.

79 sought to determine if patients with T1D and multivessel disease may benefit from CABG compared with

80 risk from combined procedures: patients with multivessel disease (multivariable OR 1.64, 95% CI 1.13

81 Symptomatic patients with multivessel disease (n = 1,829) were randomly assigned t

82 were age, anemia, congestive heart failure, multivessel disease, number of stents implanted, and use

83 he predictors of 30-day readmission included multivessel disease (odds ratio [OR], 1.97; 95% CI, 1.65

84 The effect of multivessel disease on inducibility of these perfusion a

85 In patients with multivessel disease, overall mortality and freedom from

86 p = 0.001), history of prior MI (p = 0.003), multivessel disease (p = 0.006), and advancing age (p <

87 the following contentions: For patients with multivessel disease, particularly involving the proximal

88 revascularization strategy in patients with multivessel disease presenting with cardiogenic shock co

89 aneous coronary intervention (PPCI) who have multivessel disease presenting with ST-segment elevation

90 with culprit-only stenting in patients with multivessel disease presenting with unstable angina or n

91 rt failure than white men but lower rates of multivessel disease, prior coronary artery bypass graft

92 mortality and MI rates in 1829 patients with multivessel disease randomized to CABG or PTCA.

93 n strategy in diabetic patients with complex multivessel disease remains controversial.

94 A total of 60 patients with multivessel disease requiring staged procedure at 1 mont

95 neous intervention in diabetic patients with multivessel disease results in higher mortality than cor

96 it vessel-only PCI (CO-PCI) in patients with multivessel disease, ST-segment-elevation myocardial inf

97 Killip class >/=2, baseline thrombocytosis, multivessel disease, symptom onset-to-balloon time, and

98 In subgroup analysis of patients with multivessel disease, those with a stent-like result had

99 rtery has been investigated in patients with multivessel disease to provide a minimally invasive ther

100 ic patients with acute coronary syndrome and multivessel disease treated with PCI rather than CABG ha

101 entation, diabetes mellitus, current smoker, multivessel disease, treatment of an in-stent restenotic

102 With ST-Elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or

103 ith Diabetes mellitus: Optimal management of Multivessel disease) trial, we compared patients receivi

104 ltivessel intervention in 3984 patients with multivessel disease undergoing primary percutaneous coro

105 levation myocardial infarction patients with multivessel disease was dependent on the presence of 3-v

106 ecause sensitivity for residual stenosis and multivessel disease was maximal in the high-risk subsets

107 However, the ability to detect multivessel disease was reduced with attenuation/scatter

108 es 5-year cardiac mortality in patients with multivessel disease was significantly greater after init

109 The degree of multivessel disease was similar between the two groups.

110 The rate of angiographic multivessel disease was similar in the angiography-guide

111 The extent of significant CAD (single- or multivessel disease) was highly concordant with coronary

112 tion with everolimus eluting stent (EES) for multivessel disease were included.

113 Diabetes mellitus and multivessel disease were independently associated with i

114 Diabetes mellitus and multivessel disease were more often present in the later

115 The determinants of sensitivity for multivessel disease were peak heart rate and infarct siz

116 on Investigation (BARI), 1,829 patients with multivessel disease were randomized to an initial strate

117 optimal management of patients found to have multivessel disease while undergoing primary percutaneou

118 ction, and heart failure among patients with multivessel disease who are undergoing coronary artery b

119 andomly assigned 885 patients with STEMI and multivessel disease who had undergone primary PCI of an

120 We identified patients with multivessel disease who received drug-eluting stents or

121 registries to identify 37,212 patients with multivessel disease who underwent CABG and 22,102 patien

122 y, we compared the outcomes in patients with multivessel disease who underwent CABG with the outcomes

123 who underwent CABG and 22,102 patients with multivessel disease who underwent PCI from January 1, 19

124 In patients with STEMI and multivessel disease who underwent primary PCI of an infa

125 A total of 68.9% of all stent patients with multivessel disease who were studied were IR, and 30.1%

126 ase, history of peripheral vascular disease, multivessel disease, widowhood, and lack of private insu

127 ional databases show a survival advantage in multivessel disease with coronary artery bypass grafting

128 sease undergoing index revascularization for multivessel disease with either DES or isolated CABG (n=

129 or high risk for continued medical therapy (multivessel disease with ischemia and/or left ventricula

130 y (ACUITY) trial, 1772 diabetic patients had multivessel disease with left anterior descending artery

131 ith Diabetes Mellitus: Optimal Management of Multivessel Disease) with prior probability distribution